Cited by 1,147Multiple Myeloma Research and TreatmentsBone health and treatmentsProtein Degradation and Inhibitors

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Open access

McCarthy, Philip L., Owzar, Kouros, Hofmeister, Craig C., Hurd, David D., Hassoun, Hani, Richardson, Paul G., Giralt, Sergio, Stadtmauer, Edward A., Weisdorf, Daniel J., Vij, Ravi, Moreb, Jan S., Callander, Natalie Scott, Van Besien, Koen, Gentile, Teresa, Isola, Luis, Maziarz, Richard T., Gabriel, Don A., Bashey, Asad, Landau, Heather, Martin, Thomas, Qazilbash, Muzaffar H., Levitan, Denise, McClune, Brian, Schlossman, Robert, Hars, Vera, Postiglione, John, Jiang, Chen, Bennett, Elizabeth, Barry, Susan, Bressler, Linda, Kelly, Michael, Seiler, Michele, Rosenbaum, Cara, Hari, Parameswaran, Pasquini, Marcelo C., Horowitz, Mary M., Shea, Thomas C., Devine, Steven M., Anderson, Kenneth C., Linker, Charles·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1114083PMC PMC3744390

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma. METHODS: Between April 2005 and July 2009, we randomly assigned 460 patients who were younger than 71 years of age and had stable disease or a marginal, partial, or complete response 100 days after undergoing stem-cell transplantation to lenalidomide or placebo, which was administered until disease progression. The starting dose of lenalidomide was 10 mg per day (range, 5 to 15). RESULTS: The study-drug assignments were unblinded in 2009, when a planned interim analysis showed a significantly longer time to disease progression in the lenalidomide group. At unblinding, 20% of patients who received lenalidomide and 44% of patients who received placebo had progressive disease or had died (P<0.001); of the remaining 128 patients who received placebo and who did not have progressive disease, 86 crossed over to lenalidomide. At a median follow-up of 34 months, 86 of 231 patients who received lenalidomide (37%) and 132 of 229 patients who received placebo (58%) had disease progression or had died. The median time to progression was 46 months in the lenalidomide group and 27 months in the placebo group (P<0.001). A total of 35 patients who received lenalidomide (15%) and 53 patients who received placebo (23%) died (P=0.03). More grade 3 or 4 hematologic adverse events and grade 3 nonhematologic adverse events occurred in patients who received lenalidomide (P<0.001 for both comparisons). Second primary cancers occurred in 18 patients who received lenalidomide (8%) and 6 patients who received placebo (3%). CONCLUSIONS: Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00114101.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1114083

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Analysis of Survival Data
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,269
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citation
Multiple Myeloma
Palumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,382
Self-citation
The Statistical Analysis of Failure Time Data
Klein, J. P., Kalbfleisch, J. D., & Prentice, R. L. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,248
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Multiple myeloma
Raje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164
Self-citation

Show all 42 references

Research works printed but not linked: 2

10.1001/archinte.135.1.147 · DOI
10.2307/2281868 · DOI · Paper page

Sorted by citations

Items 101–200 of 1,000

Salvage Second Hematopoietic Cell Transplantation in Myeloma
Michaelis, L. C., Saad, A. A., Zhong, X., Le‐Rademacher, J. G., Freytes, C. O., Marks, D. I., Lazarus, H. M., Bird, J. M., Holmberg, L., Kamble, R. T., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.01.004 · Cited by 108
Self-citation
The role of P-glycoprotein in drug resistance in multiple myeloma
Abraham, J., Salama, N. N., & Azab, A. K. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.907890 · Cited by 106
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
Ludwig, H., Delforge, M., Facon, T. T. F., Einsele, H., Gay, F., Moreau, P., Avet‐Loiseau, H., Boccadoro, M., Hájek, R., Mohty, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0040-1 · Cited by 104
Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy
Shortt, J., Hsu, A. K., & Johnstone, R. W. (2013) · Oncogene · doi:10.1038/onc.2012.599 · Cited by 103
Multiple Myeloma Treatment Transformed: A Population-Based Study of Changes in Initial Management Approaches in the United States
Warren, J. L., Harlan, L. C., Stevens, J. L., Little, R. F., & Abel, G. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3323 · Cited by 101
Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation
Alsina, M., Becker, P. S., Zhong, X., Adams, A. J., Hari, P., Rowley, S. D., Stadtmauer, E. A., Vesole, D. H., Logan, B. R., Weisdorf, D. J., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.04.014 · Cited by 101
Self-citation
Recent updates on CAR T clinical trials for multiple myeloma
Lin, Q., Zhao, J., Song, Y., & Liu, D. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1092-1 · Cited by 101
How we manage autologous stem cell transplantation for patients with multiple myeloma
Gertz, M. A., & Dingli, D. (2014) · Blood · doi:10.1182/blood-2014-03-544759 · Cited by 100
Management of multiple myeloma in the newly diagnosed patient
Mateos, M., & Miguel, J. F. S. (2017) · Hematology · doi:10.1182/asheducation-2017.1.498 · Cited by 98
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
Diamond, B. T., Korde, N., Lesokhin, A. M., Smith, E. L., Shah, U. A., Mailankody, S., Hultcrantz, M. L., Hassoun, H., Lu, S. X., Tan, C. R. C., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00130-7 · Cited by 94
Self-citation
Maintenance Treatment and Survival in Patients With Myeloma
Gay, F., Jackson, G. H., Rosiñol, L., Holstein, S. A., Moreau, P., Spada, S., Davies, F. E., Lahuerta, J. J., Leleu, X. P., Bringhen, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2961 · Cited by 94
Self-citation
Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time
Kumar, S. K., Dispenzieri, A. A., Fraser, R. A., Fei, M., Akpek, G., Cornell, R. F., Kharfan‐Dabaja, M. A., Freytes, C. O., Hashmi, S. K., Hildebrandt, G. C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.331 · Cited by 92
Self-citation
How I treat high-risk myeloma
Lonial, S., Boise, L., & Kaufman, J. L. (2015) · Blood · doi:10.1182/blood-2015-06-653261 · Cited by 88
Academic, Foundation, and Industry Collaboration in Finding New Therapies
Ramsey, B. W., Nepom, G. T., & Lonial, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1612575 · Cited by 87
Promising therapies in multiple myeloma
Bianchi, G., Richardson, P. G. G., & Anderson, K. C. (2015) · Blood · doi:10.1182/blood-2015-03-575365 · Cited by 86
Self-citation
Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
Zhou, S. Y., Wang, F., Hsieh, T.-C., WU, J. M., & Wu, E. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990198 · Cited by 86
A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity
Liu, J., Song, T., Zhou, W., Xing, L., Wang, S., Ho, M., Peng, Z., Tai, Y.-T., Hideshima, T., Anderson, K. C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0205-y · Cited by 83
Self-citation
Smoldering multiple myeloma requiring treatment: time for a new definition?
Dispenzieri, A. A., Stewart, A. K., Chanan-Khan, A. A., Rajkumar, S. V., Kyle, R. A., Fonseca, R., Kapoor, P., Bergsagel, P. L., McCurdy, A. B. R., Gertz, M. A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-520890 · Cited by 83
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
Dytfeld, D., Wróbel, T., Jamroziak, K., Kubicki, T., Robak, P. J., Walter‐Croneck, A., Czyż, J., Tyczyńska, A., Druzd‐Sitek, A., Giannopoulos, K., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00738-0 · Cited by 83
Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.
Dispenzieri, A., Seenithamby, K., Lacy, M., Kumar, S. K., Buadi, F., Hayman, S., Dingli, D., Litzow, M., Gastineau, D., Inwards, D., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.53 · Cited by 82
Solubility parameter of lenalidomide for predicting the type of solubility profile and application of thermodynamic model
Yang, Z., Shao, D., & Zhou, G. (2018) · The Journal of Chemical Thermodynamics · doi:10.1016/j.jct.2018.12.035 · Cited by 81
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients
Jones, J. R., Weinhold, N., Ashby, C., Walker, B. A., Wardell, C. P., Pawlyn, C., Rasche, L., Melchor, L., Cairns, D. A., Gregory, W. M., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.202200 · Cited by 85
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
Jones, J. R., Cairns, D. A., Gregory, W. M., Collett, C., Pawlyn, C., Sigsworth, R., Striha, A., Henderson, R., Kaiser, M., Jenner, M. W., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.114 · Cited by 81
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
Rajkumar, S. V., & Harousseau, J. L. (2016) · Blood · doi:10.1182/blood-2016-09-692947 · Cited by 80
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results
Gay, F., Magarotto, V., Crippa, C., Pescosta, N., Guglielmelli, T., Cavallo, F., Pezzatti, S., Ferrari, S., Liberati, A. M., Oliva, S., et al. (2013) · Blood · doi:10.1182/blood-2013-02-483073 · Cited by 80
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
Moreau, P., Joshua, D. E., Chng, W.-J., Palumbo, A. P., Goldschmidt, H., Hájek, R., Facon, T. T. F., Ludwig, H., Pour, L., Niesvizky, R., et al. (2016) · Leukemia · doi:10.1038/leu.2016.186 · Cited by 77
The application and biology of immunomodulatory drugs (IMiDs) in cancer
Pan, B., & Lentzsch, S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.004 · Cited by 76
Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care
Damlaj, M., Fakih, R. O. E., & Hashmi, S. K. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.07.003 · Cited by 75
Second primary malignancies in multiple myeloma: A review
Poh, C., Keegan, T. H. M., & Rosenberg, A. S. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100757 · Cited by 75
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance
Usmani, S. Z., Sexton, R. E., Hoering, A., Heuck, C. J., Nair, B. P., Waheed, S., Alsayed, Y. M., Chauhan, N., Ahmad, N., Atrash, S., et al. (2012) · Blood · doi:10.1182/blood-2012-04-421883 · Cited by 75
A systematic review of health‐related quality of life in longitudinal studies of myeloma patients
Nielsen, L. K., Jarden, M., Andersen, C. L., Frederiksen, H., & Abildgaard, N. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12882 · Cited by 75
Multiple Myeloma, Version 2.2016
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C. L., Djulbegović, B., Fung, H. C. H., Gasparetto, C., Godby, K. N., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0167 · Cited by 75
Self-citation
Current approaches to management of newly diagnosed multiple myeloma
Goel, U., Usmani, S. Z., & Kumar, S. K. (2022) · American Journal of Hematology · doi:10.1002/ajh.26512 · Cited by 76
Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma
Lemieux‐Blanchard, É., Hulin, C., Caillot, D., Tardy, S., Dorvaux, V., Michel, J., Gastinne, T., Rossi, C., Legouge, C., Touzeau, C., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.11.013 · Cited by 72
Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs
Booth, C. M., Eisenhauer, E. A., Gyawali, B., & Tannock, I. F. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01423 · Cited by 75
Clinical value of molecular subtyping multiple myeloma using gene expression profiling
Weinhold, N., Heuck, C. J., Rosenthal, A., Thanendrarajan, S., Epstein, J., van Rhee, F., Zangari, M., Hoering, A., Tian, E., Davies, F. E., et al. (2015) · Leukemia · doi:10.1038/leu.2015.309 · Cited by 71
Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics
Razavi, P., Rand, K. A., Cozen, W., Chanan-Khan, A. A., Usmani, S. Z., & Ailawadhi, S. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.19 · Cited by 71
Guidelines for screening and management of late and long‐term consequences of myeloma and its treatment
Snowden, J. A., Greenfield, D., Bird, J. M., Boland, E. G., Bowcock, S. J., Fisher, A., Low, E., Morris, M., Yong, K., Pratt, G., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14514 · Cited by 69
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial
Rosiñol, L., Oriol, A., Teruel, A. I., de la Guía, A. L., Blanchard, M., de la Rubia, J., Granell, M., Sampol, M., Palomera, L., González, Y., et al. (2017) · Leukemia · doi:10.1038/leu.2017.35 · Cited by 69
Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
Pittari, G., Vago, L., Festuccia, M. B., Bonini, C., Mudawi, D., Giaccone, L., & Bruno, B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01444 · Cited by 73
Thalidomide and its analogues in the treatment of Multiple Myeloma
Latif, T., Chauhan, N., Khan, R. Z., Moran, A. E., & Usmani, S. Z. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-27 · Cited by 70
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis
Palladini, G. O., Russo, P., Milani, P., Foli, A., Lavatelli, F., Nuvolone, M., Perlini, S., & Merlini, G. (2012) · Haematologica · doi:10.3324/haematol.2012.073593 · Cited by 68
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Moreau, P., Zamagni, E., & Mateos, M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0200-1 · Cited by 68
Current strategies for treatment of relapsed/refractory multiple myeloma
Laubach, J. P., Voorhees, P. M., Hassoun, H., Jakubowiak, A. J., Lonial, S., & Richardson, P. G. G. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.882764 · Cited by 68
Self-citation
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
Goldschmidt, H., Mai, E. K., Dürig, J., Scheid, C., Weisel, K. C., Kunz, C., Bertsch, U., Hielscher, T., Merz, M., Munder, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0724-1 · Cited by 67
Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations
Greco, R., Ruggeri, A., McLornan, D. P., Snowden, J. A., Alexander, T., Angelucci, E., Averbuch, D., Bazarbachi, A. A., Hazenberg, M. D., Kałwak, K., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02701-3 · Cited by 69
Therapeutic Advancements in Multiple Myeloma
Gozzetti, A., Candi, V., Papini, G., & Bocchia, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00241 · Cited by 67
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma
Rosiñol, L., Oriol, A., Ríos, R., Blanchard, M. J., Jarque, I., Bargay, J., Hernández, M. T., Cabañas, V., Carrillo‐Cruz, E., Sureda, A. M., et al. (2023) · Blood · doi:10.1182/blood.2022019531 · Cited by 66
How I treat first relapse of myeloma
Harousseau, J. L., & Attal, M. (2017) · Blood · doi:10.1182/blood-2017-03-726703 · Cited by 67
Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies
Keren, D. F., Bocsi, G., Billman, B. L., Etzell, J., Faix, J. D., Kumar, S., Lipe, B. C., McCudden, C. R., Montgomery, R., Murray, D. L., et al. (2021) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0794-cp · Cited by 65
Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers
Mohty, M., & Harousseau, J. (2014) · Haematologica · doi:10.3324/haematol.2013.096149 · Cited by 66
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report
Morton, L. M., Saber, W., Baker, K. S., Barrett, A. J., Bhatia, S., Engels, E. A., Gadalla, S. M., Kleiner, D. E., Pavletic, S. Z., & Burns, L. J. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.09.005 · Cited by 68
Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis
Mahindra, A. K., Hari, P., Fraser, R. A., Fei, M., Huang, J., Berdeja, J. G., Callander, N. S., Costa, L. J., Díaz, M. Á., Freytes, C. O., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.198 · Cited by 65
Self-citation
Multiple myeloma: Role of autologous transplantation
Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101929 · Cited by 68
Infection risk with immunomodulatory and proteasome inhibitor–based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis
Teh, B. W., Harrison, S. J., Worth, L. J., Thursky, K., & Slavin, M. A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.025 · Cited by 64
Single versus tandem high‐dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long‐term results from the phase III GMMG ‐ HD 2 trial
Mai, E. K., Benner, A., Bertsch, U., Brossart, P., Hänel, A., Kunzmann, V., Naumann, R., Neben, K., Egerer, G., Ho, A. D., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13994 · Cited by 67
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance
Palazzo, M. A., Shah, G. L., Copelan, O. R., Seier, K. P., Devlin, S. M., Maloy, M., Kenny, S., Hassoun, H., Korde, N., Lendvai, N. K., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.12.795 · Cited by 63
Self-citation
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
Goldschmidt, H., Baertsch, M., Schlenzka, J., Becker, N., Habermehl, C., Hielscher, T., Raab, M., Hillengaß, J., Sauer, S., Müller‐Tidow, C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0948-0 · Cited by 63
Gene expression profile alone is inadequate in predicting complete response in multiple myeloma
Amin, S. B., Yip, W.-K., Minvielle, S., Broyl, A., Li, Y., Hanlon, B. M., Swanson, D. M., Shah, P. K., Moreau, P., van der Holt, B., et al. (2014) · Leukemia · doi:10.1038/leu.2014.140 · Cited by 61
Self-citation
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
Offidani, M., Corvatta, L., Maracci, L., Liberati, A. M., Ballanti, S., Attolico, I., Caraffa, P., Alesiani, F., di Toritto, T. C., Gentili, S., et al. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.58 · Cited by 62
Trial Watch: Lenalidomide-based immunochemotherapy
Semeraro, M., Vacchelli, E., Eggermont, A. M. M., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.26494 · Cited by 61
RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
Zhou, N., Gutiérrez-Uzquiza, Á., Zheng, X. Y., Chang, R., Vogl, D. T., Garfall, A. L., Bernabei, L. L., Saraf, A., Florens, L. A., Washburn, M. P., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0403-2 · Cited by 63
Autologous retransplantation for patients with recurrent multiple myeloma
Sellner, L., Heiß, C., Benner, A., Raab, M. S., Hillengaß, J., Hose, D., Lehners, N., Egerer, G., Ho, A. D., Goldschmidt, H., et al. (2013) · Cancer · doi:10.1002/cncr.28104 · Cited by 59
Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma
Kaufman, G. P., Gertz, M. A., Dispenzieri, A. A., Lacy, M. Q., Buadi, F. K., Dingli, D., Hayman, S. R., Kapoor, P., Lust, J. A., Russell, S. J., et al. (2015) · Leukemia · doi:10.1038/leu.2015.287 · Cited by 61
Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression‐free survival in multiple myeloma
Maiolino, Â., Hungria, V., Garnica, M., Oliveira-Duarte, G. B., de Oliveira, L. C. O., Mercante, D., MIRANDA, E. C. M., Quero, A. A., Peres, A. L., Barros, J. C., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23274 · Cited by 59
Allogeneic stem cell transplantation for multiple myeloma: is there a future?
Dhakal, B., Vesole, D. H., & Hari, P. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.325 · Cited by 61
Self-citation
Update on the role of lenalidomide in patients with multiple myeloma
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718775629 · Cited by 59
Self-citation
Perspectives on the Treatment of Multiple Myeloma
Rafae, A., van Rhee, F., & Hadidi, S. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad306 · Cited by 65
Phase I/ II study exploring ImMucin, a pan‐major histocompatibility complex, anti‐ MUC 1 signal peptide vaccine, in multiple myeloma patients
Carmon, L., Avivi, I. M., Kovjazin, R., Zuckerman, T., Dray, L., Gatt, M. E., Or, R., & Shapira, M. Y. (2014) · British Journal of Haematology · doi:10.1111/bjh.13245 · Cited by 58
An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma
Offidani, M., Corvatta, L., Caraffa, P., Gentili, S., Maracci, L., & Leoni, P. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s49187 · Cited by 58
Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients
Roeker, L. E., Larson, D. R., Kyle, R. A., Kumar, S. K., Dispenzieri, A. A., & Rajkumar, S. V. (2013) · Leukemia · doi:10.1038/leu.2013.34 · Cited by 56
Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
Dima, D., Dower, J., Comenzo, R. L., & Varga, C. (2020) · Cancer Management and Research · doi:10.2147/cmar.s212526 · Cited by 56
Synthesis of substituted amines and isoindolinones: catalytic reductive amination using abundantly available AlCl3/PMHS
Kumar, V., Sharma, S., Sharma, U. K., Singh, B., & Kumar, N. (2012) · Green Chemistry · doi:10.1039/c2gc36305d · Cited by 55
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics
Chakraborty, R., Muchtar, E., Kumar, S. K., Jevremović, D., Buadi, F. K., Dingli, D., Dispenzieri, A. A., Hayman, S. R., Hogan, W. J., Kapoor, P., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.01.076 · Cited by 55
Current Treatment Strategies for Multiple Myeloma
Branagan, A. R., Lei, M. M., Lou, U. Y., & Raje, N. S. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00244 · Cited by 56
Treatment for patients with newly diagnosed multiple myeloma in 2015
Mateos, M., Ocio, E. M., Paiva, B., Rosiñol, L., Martínez‐López, J., Bladé, J., Lahuerta, J. J., García‐Sánz, R., & Miguel, J. F. S. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.06.001 · Cited by 55
Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years
Engelhardt, M. M., Ihorst, G., Landgren, O., Pantić, M., Reinhardt, H., Waldschmidt, J. M., May, A. M., Schumacher, M. C., Kleber, M., & Wäsch, R. (2015) · Haematologica · doi:10.3324/haematol.2015.127548 · Cited by 55
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review
Wang, Y., Yang, F., Shen, Y., Zhang, W., Wang, J., Chang, V. T.-S., Andersson, B. S., Qazilbash, M. H., Champlin, R. E., Berenson, J. R., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv342 · Cited by 57
Self-citation
Ixazomib for the treatment of multiple myeloma
Gentile, M., Offidani, M., Vigna, E., Corvatta, L., Recchia, A. G., Morabito, L., Morabito, F., & Gentili, S. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1065250 · Cited by 53
Lenalidomide Treatment for Multiple Myeloma: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Yang, B. Y., Yu, R., Chi, X.-H., & Lu, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064354 · Cited by 52
Multiple Myeloma: An Update
Al‐Farsi, K. (2013) · Oman Medical Journal · doi:10.5001/omj.2013.02 · Cited by 53
Herpes Zoster in Autologous Hematopoietic Cell Transplant Recipients in the Era of Acyclovir or Valacyclovir Prophylaxis and Novel Treatment and Maintenance Therapies
Sahoo, F., Hill, J. A., Xie, H., Leisenring, W. M., Yi, J., Goyal, S., Kimball, L. E., Lee, I., Seo, S., Davis, C., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.12.620 · Cited by 52
FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
Pulte, E. D., Dmytrijuk, A., Nie, L., Goldberg, K. B., McKee, A. E., Farrell, A. T., & Pazdur, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0440 · Cited by 52
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
Miguel, J. F. S., Weisel, K. C., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Moreau, P., Baños, A., Oriol, A., Garderet, L., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.125864 · Cited by 51
Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
Chhabra, S. (2017) · Pharmaceuticals · doi:10.3390/ph10020040 · Cited by 52
Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing
Kumar, S. K., Buadi, F. K., & Rajkumar, S. V. (2018) · Blood · doi:10.1182/blood-2018-08-825349 · Cited by 51
The future of autologous stem cell transplantation in myeloma
van Rhee, F., Giralt, S., & Barlogie, B. (2014) · Blood · doi:10.1182/blood-2014-03-561985 · Cited by 50
Self-citation
Subsequent Malignant Neoplasms after Hematopoietic Cell Transplantation
Socié, G., Baker, K. S., & Bhatia, R. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.10.005 · Cited by 51
Immunotherapy based on bispecific T‐cell engager with hIgG 1 Fc sequence as a new therapeutic strategy in multiple myeloma
Zou, J., Chen, D., Zong, Y., Ye, S., Tang, J., Meng, H., An, G., Zhang, X., & Yang, L. (2015) · Cancer Science · doi:10.1111/cas.12631 · Cited by 50
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
Oliva, S., Bruinink, D. H. O., Říhová, L., D’Agostino, M., Pantani, L., Capra, A., van der Holt, B., Troia, R., Petrucci, M. T., Villanova, T., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00498-0 · Cited by 50
Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression
Jones, R. J., Iempridee, T., Wang, X., Lee, H. C., Mertz, J. E., Kenney, S. C., Lin, H. C., Baladandayuthapani, V., Dawson, W. O., Shah, J. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2242 · Cited by 48
Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained response
Lehners, N., Becker, N., Benner, A., Pritsch, M., Löpprich, M., Mai, E. K., Hillengaß, J., Goldschmidt, H., & Raab, M. S. (2017) · Cancer Medicine · doi:10.1002/cam4.1283 · Cited by 48
Chemotherapy and Beyond
Atkins, S., & He, F. C. (2019) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2019.01.001 · Cited by 49
Venous thromboembolism risk with contemporary lenalidomide‐based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta‐analysis
Chakraborty, R., Riaz, I. B., Malik, S. U., Marneni, N., Garcia, A. M., Anwer, F., Khorana, A. A., Rajkumar, S. V., Kumar, S. K., Murad, M. H., et al. (2020) · Cancer · doi:10.1002/cncr.32682 · Cited by 48
Second malignancies in multiple myeloma; emerging patterns and future directions
Maclachlan, K. H., Diamond, B. T., Maura, F., Hillengaß, J., Turesson, I., Landgren, O., & Kazandjian, D. G. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101144 · Cited by 48
Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis
Saleem, K., Franz, J. K., Klem, M. L., Yabes, J. G., Boyiadzis, M. M., Jones, J. R., Shaikh, N., & Lontos, K. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00289-7 · Cited by 50
Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study
Bilmon, I., Ashton, L. J., Marsney, R. E. L., Dodds, A. J., O'Brien, T. A., Wilcox, L., Nivison‐Smith, I., Daniels, B. J., Vajdic, C. M., CAST study group, et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.13 · Cited by 47
New Cancers after Autotransplantations for Multiple Myeloma
Mahindra, A. K., Raval, G. G., Mehta, P., Brazauskas, R., Zhang, M., Zhong, X., Bird, J. M., Freytes, C. O., Hale, G. A., Herzig, R. H., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.12.028 · Cited by 47
Self-citation
Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis
Li, Y., YinHui, T., Yunliang, Z., & Sun, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16235 · Cited by 47
Secondary Primary Malignancies in Multiple Myeloma: An Old Nemesis Revisited
Yang, J., Terebelo, H. R., & Zonder, J. A. (2012) · Advances in Hematology · doi:10.1155/2012/801495 · Cited by 47

Authors: McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., Moreb, J. S., Callander, N. S., Van Besien, K., Gentile, T., Isola, L., Maziarz, R. T., Gabriel, D. A., Bashey, A., Landau, H., Martin, T., Qazilbash, M. H., Levitan, D., McClune, B., Schlossman, R., Hars, V., Postiglione, J., Jiang, C., Bennett, E., Barry, S., Bressler, L., Kelly, M., Seiler, M., Rosenbaum, C., Hari, P., Pasquini, M. C., Horowitz, M. M., Shea, T. C., Devine, S. M., Anderson, K. C., & Linker, C.
Affiliations: Roswell Park Comprehensive Cancer Center (US)
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
Duke University (US)
Memorial Sloan Kettering Cancer Center (US)
Dana-Farber Cancer Institute (US)
Abramson Cancer Center (US)
University of Minnesota Medical Center (US)
Washington University in St. Louis (US)
University of Florida (US)
University of Wisconsin–Madison (US)
State University of New York (US)
Mount Sinai Hospital (US)
Oregon Health & Science University (US)
University of North Carolina at Chapel Hill (US)
BMT Group (United States) (US)
University of California, San Francisco (US)
The University of Texas MD Anderson Cancer Center (US)
University of Chicago (US)
University of Chicago Medical Center (US)
Medical College of Wisconsin (US)
ORCID: McCarthy, Philip L.
Owzar, Kouros
Hofmeister, Craig C.
Hassoun, Hani
Richardson, Paul G.
Giralt, Sergio
Stadtmauer, Edward A.
Weisdorf, Daniel J.
Vij, Ravi
Moreb, Jan S.
Callander, Natalie Scott
Gentile, Teresa
Isola, Luis
Maziarz, Richard T.
Landau, Heather
Martin, Thomas
Qazilbash, Muzaffar H.
McClune, Brian
Jiang, Chen
Bennett, Elizabeth
Kelly, Michael
Rosenbaum, Cara
Hari, Parameswaran
Pasquini, Marcelo C.
Horowitz, Mary M.
Devine, Steven M.
Anderson, Kenneth C.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-05-10
Volume: 366
Issue: 19
Pages: 1770-1781
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1114083
PMC: PMC3744390
OpenAlex: W2125721471
Semantic Scholar: b20a8f57aae32a45c1804976b107b4ba1609688f
Cited by: 1,147
References: 42
Citations by year: 2026: 28 · 2025: 30 · 2024: 40 · 2023: 40 · 2022: 51 · 2021: 74 · 2020: 81 · 2019: 70 · 2018: 82 · 2017: 104 · 2016: 107 · 2015: 100 · 2014: 113 · 2013: 144 · 2012: 81
FWCI: 93.26
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
Funders: National Heart, Lung, and Blood Institute (U10HL069334, U10HL069301, U10HL069348, U10HL109526, U01HL069294, U10HL069294, U10HL069330, U10HL069315, U10HL069290, U10HL069286, UG1HL069286, UG1HL069315)
National Cancer Institute (U10CA033601, P50CA100707, U10CA031946, U10CA021115, U24CA076518)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords: lenalidomide, multiple myeloma, autologous stem cell transplantation, maintenance therapy, time to progression, overall survival, secondary malignancies, hematologic adverse events, drug toxicity
MeSH terms: Lenalidomide, Adult, Aged, Antineoplastic Agents, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Neoplasms, Second Primary, Disease-Free Survival, Stem Cell Transplantation, Maintenance Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks